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Vitamin B12 deficiency 
and altered one‑carbon 
metabolites in early pregnancy 
is associated with maternal obesity 
and dyslipidaemia
Antonysunil Adaikalakoteswari1,2, Catherine Wood3, Theresia H. Mina4, Craig Webster5, 
Ilona Goljan3, Yonas Weldeselassie2, Rebecca M. Reynolds4 & Ponnusamy Saravanan2,3*
Vitamin B12 (B12) is a micronutrient essential for one‑carbon (1C) metabolism. B12 deficiency disturbs 
the 1C cycle and alters DNA methylation which is vital for most metabolic processes. Studies show 
that B12 deficiency may be associated with obesity, insulin resistance and gestational diabetes; 
and with obesity in child‑bearing women. We therefore hypothesised that the associations between 
B12 deficiency, BMI and the metabolic risk could be mediated through altered 1C metabolites in 
early pregnancy. We explored these associations in two different early pregnancy cohorts in the UK 
(cohort 1; n = 244 and cohort 2; n = 60) with anthropometric data at 10–12 weeks and plasma/serum 
sampling at 16–18 weeks. B12, folate, total homocysteine (tHcy), methionine, MMA, metabolites 
of 1C metabolism (SAM, SAH) and anthropometry were measured. B12 deficiency (< 150 pmol/l) in 
early pregnancy was 23% in cohort 1 and 18% in cohort 2. Regression analysis after adjusting for 
likely confounders showed that B12 was independently and negatively associated with BMI (Cohort 
1: β = − 0.260, 95% CI (− 0.440, − 0.079), p = 0.005, Cohort 2: (β = − 0.220, 95% CI (− 0.424, − 0.016), 
p = 0.036) and positively with HDL cholesterol (HDL‑C) (β = 0.442, 95% CI (0.011,0.873), p = 0.045). 
We found that methionine (β = − 0.656, 95% CI (− 0.900, − 0.412), p < 0.0001) and SAH (β = 0.371, 
95% CI (0.071, 0.672), p = 0.017) were independently associated with triglycerides. Low B12 status 
and alteration in metabolites in 1C metabolism are common in UK women in early pregnancy and 
are independently associated with maternal obesity and dyslipidaemia. Therefore, we suggest B12 
monitoring in women during peri‑conceptional period and future studies on the pathophysiological 
relationship between changes in 1C metabolites and its association with maternal and fetal outcomes 
on larger cohorts. This in turn may offer potential to reduce the metabolic risk in pregnant women and 
their offspring.
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SD  Standard deviation
SDS  Standard deviation scores
T2D  Type 2 diabetes
The rise in obesity is a global challenge and is rapidly increasing in reproductive age. This influences obesity and 
increased risk of adverse pregnancy outcomes during pregnancy, which reinforces the risk to childhood obesity 
and other non-communicable diseases in adult  life1. It is known that maternal macronutrients influence obesity, 
but emerging evidence suggest micronutrient deficiency such as vitamin B12, could play a role in  adipogenesis2,3. 
B12 is involved in 1C metabolism and supplies the methyl groups required for the DNA methylation, which is 
key for maternal health and optimal fetal growth and development. Deficiency in B12 alters the levels of total 
homocysteine (tHcy), methionine, methylmalonic acid (MMA) and metabolites of 1C cycle including S-adenosyl 
methionine (SAM) and S-adenosyl homocysteine (SAH), which is associated with various adverse pregnancy 
outcomes and cardiovascular  complications4. Since epigenetic modifications play a major role on the pathogenesis 
of many disease states, recent research predicts that metabolites of 1C metabolism might have an intermediate 
effect in adverse metabolic  outcomes5.
Several observational and epidemiological studies have shown that low B12 is associated with high  BMI6, 
insulin resistance (IR)7, increasing severity of glucose  tolerance8 and adverse lipid profiles in type 2 diabetes 
(T2D)9. Supporting this, a recent Mendelian Randomization  study10 reported a possible causal relationship 
between B12 and fasting glucose and β-cell function. A series of studies during pregnancy in both South  Asian11,12 
and  Caucasian6 have shown association of low B12 with obesity, IR and higher risk of GDM. In children and 
adolescents, increase in  BMI13 and  IR14 have been associated with low B12 levels. Furthermore, studies in early 
pregnancy have focussed on association between lower maternal micronutrient status (B12, folate, iron) with 
pre-pregnancy overweight and obesity in  mothers15,16,17, with lower micronutrients in low-birth weight  infants18 
and with higher BMI and heart rate in children at age 5–619. Our in vitro studies have shown that B12 deficiency 
in adipocytes altered DNA methylation  levels2 of the transcription factors of lipid  regulation2 and the adipose 
derived miRNAs targeting  IR3 thereby suggesting that B12 deficiency dysregulates epigenetic mechanisms.
Though several studies have found an association between B12 and metabolic risk, there are very few stud-
ies on 1C metabolites in pregnancy. Our pilot study showed association of 1C metabolites with low B12 and 
increased  triglycerides20. A study in Brazil reported that lower maternal B12 concentration is associated with 
higher tHcy and lower SAM:SAH in  newborns21. A Danish cross-sectional study in non-pregnant adults found 
that plasma 1C metabolites positively associated with higher risk of metabolic  dysfunction22. In addition, a recent 
study of mother-infant dyads identified changes in methylation patterns in 993 CpG sites, which were related 
to altered 1C metabolite indices over pregnancy, thereby suggesting the impact of different 1C metabolites on 
regulation of DNA methylation at multiple  sites23. This evidence supports that altered 1C metabolites, adversely 
affect epigenetic mechanisms and metabolic health of both mother and offspring. Since underlying nutritional 
status influences the predictors of DNA methylation, studying these 1C biomarkers at early pregnancy, the 
embryonic development period involving complex epigenetic remodelling will extend our understanding of 
association of 1C metabolites with metabolic risk.
Furthermore, understanding the early life contributors will be crucial for delineating the risk factors and 
their mechanisms leading to maternal obesity and metabolic risk. This may inform targeted implementation of 
obesity prevention in early pregnancy. We therefore hypothesise that the associations between B12 deficiency, 
BMI and the metabolic risk could be mediated through altered 1C metabolites in early pregnancy. Our current 
study investigated the prevalence of B12 deficiency and the associated changes in tHcy, methionine, MMA and 
metabolites of 1C metabolism (SAM and SAH) during early pregnancy. We also report their association with 
maternal obesity and dyslipidemia.
Research design and methods
Study population. Cohort 1. The study was conducted in George Eliot Hospital, Nuneaton, UK. Pregnant 
women (n = 244) who met the inclusion criteria of women with singleton pregnancy, free of chronic diseases or 
any other pregnancy complications and delivered full-term (37–42 weeks of gestation) healthy infant were in-
cluded in this study. All pregnant women provided blood samples between 16 and 18 weeks of their pregnancy as 
part of their routine care. Data on age, weight, smoking, alcohol, parity and socioeconomic status were obtained 
from pregnancy records. The samples were stored at − 80 °C and later analysed for metabolites. All methods were 
carried out in accordance with the approved ethical guidelines. The study was approved by the NHS Research 
Ethics Committee (12/LO/0239) and all subjects gave written informed consent.
Cohort 2. This study was conducted in the Antenatal Metabolic Clinic, Simpson’s Centre for Reproductive 
Health, Royal Infirmary of Edinburgh. Pregnant women (n = 60) identified during their first community mid-
wifery visit having a BMI ≥ 40 and lean controls with BMI ≤ 25 were invited to participate in a prospective cohort 
study from 2008 to  201224. Information on age, parity, smoking status and social and demographic data were 
collected. The main exclusions were pre-existing diabetes and major anomalies. Women who developed GDM or 
did not undergo an oral glucose tolerance test at 24–28 weeks’ gestation or developed pre-eclampsia or delivered 
< 37 weeks’ gestation were excluded from analyses. Venous blood samples were collected at 16–18 weeks’ gesta-
tion after an overnight fast and samples were stored at − 80 °C for later determination of metabolites. All research 
methods were performed in accordance with relevant guidelines and regulations. Ethical approval was obtained 
from the Lothian NHS Research Ethics Committee, and all subjects gave informed written consent (REC refer-
ence number 08/S1101/39)25.
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Analytical determinations. Serum B12 and folate were determined by electro-chemiluminescent immu-
noassay using a Roche Cobas immunoassay analyzer (Roche Diagnostics, UK). We used 150–660 pmol/l for 
serum B12 and 6–37 nmol/l for serum folate as normal ranges, respectively. The inter-assay coefficient of vari-
ations for B12 and folate were 3.9% and 3.7%,  respectively26. B12 deficiency was defined as B12 levels below 
150 pmol/l, borderline B12 deficiency as 150–220 pmol/l and folate deficiency as below 6 nmol/l. Excess folate 
is defined as > 37 nmol/l (upper limit of detection by the assay). Measurement of tHcy, methionine, MMA and 
metabolites of 1C metabolism (SAM and SAH) were determined in plasma by stable isotopic dilution analysis 
liquid chromatography using an API 6,500 QTrap tandem mass spectrometer (Applied Biosystems, UK)20. Glu-
cose concentrations were measured by a hexokinase method (Randox Laboratories, Co. Antrim, UK), total cho-
lesterol, HDL cholesterol (HDL-C), (Olympus Diagnostics, Watford, UK) and triglycerides (Alpha Laboratories, 
Eastleigh, UK) were measured by colorimetric methods.
Statistical analysis. Continuous data are reported as mean ± standard deviation (SD). Categorical data are 
reported in percentages. The distributions of the data such as B12, folate, tHcy, MMA, methionine, SAM, SAH, 
cholesterol, triglycerides and HDL-C were skewed; these data were log-transformed before analyses. Student’s 
t-test was used for comparison of groups. Pearson’s correlation was used to compare the variables. Variables that 
showed significant associations were included as independent variables in the multiple linear regression analyses 
and adjusted for confounders such as age, smoking, alcohol, parity, BMI, B12, folate, tHcy, MMA, methionine, 
SAM and SAH. To facilitate comparison, dependent and independent variables were converted into standard 
deviation scores (SDS). The data are presented as SDS change in dependent variable per SDS change in BMI, 
triglycerides and HDL-C. All tests were two-sided, and p-values of < 0.05 were considered to be statistically sig-
nificant. All analyses were performed using SPSS Statistics version 21 (IBM Corp, NY, USA)26.
Results
Baseline characteristics. The clinical characteristics of pregnant women from two cohorts are shown in 
Table 1. All women were recruited in early pregnancy at 16–18 weeks. Their booking BMI were collected at 
10–12 weeks of gestation. Significant proportion of women were obese and reported higher rates of smoking and 
alcohol intake during pregnancy (Table 1). We found the rates of B12 and borderline B12 deficiency were 23 and 
36% in cohort 1 and 18 and 43% in cohort 2, respectively. However, we did not observe any folate deficiency in 
either of these cohorts (Table 1).
Association of B12 with metabolic risk factors in early pregnancy. In both cohorts, B12 was nega-
tively correlated with BMI, tHcy and MMA; and positively correlated with SAM/SAH (Fig. 1A–H). In addition, 
in cohort 2, there was evidence of association of B12 with lipid parameters such as negative correlation with 
triglycerides and positive correlation with HDL-C (Fig. 2A–B). To further examine the independent associa-
tion of B12 and 1C metabolites with these risk factors, multiple regression analyses were carried out including 
the potential cofounders such as age, smoking, alcohol, parity, and socio-economic status. We found that B12 
remained independently associated with BMI (Cohort 1: β = − 0.260, 95% CI (− 0.440, − 0.079), p = 0.005, Cohort 
2: (β = − 0.220, 95% CI (− 0.424, − 0.016), p = 0.036) when adjusted for all co-variates (Table 2).
Table 1.  Clinical characteristics of pregnant women at early pregnancy. Data are mean ± SD; Categorical 
values are presented as percentage.
Variables
Cohort 1
(n = 244)
Cohort 2
(n = 60)
Lifestyle/demographics
Age (years) 27.6 ± 5.7 33.2 ± 4.4
Socio-economic status (Deprivation Quintile) 3.10 ± 1.27 2.52 ± 1.93
Smoking (%) 19.2 48.3
Alcohol (%) 16.4 76.5
Parity (%)
 0
 1
 >  = 2
45.9
37.2
16.9
58.3
28.3
13.3
Anthropometry
Booking visit BMI (kg/m2) 26.5 ± 5.5 32.6 ± 11.2
Obesity (%) 18.4 45.0
Micronutrients
B12 (pmol/l) 223 ± 99 233 ± 100
B12 deficiency (%) 23.0 18.3
Folate (nmol/l) 25.8 ± 10.1 28.7 ± 11.6
Folate deficiency (%) 0 0
High folate levels (%) 3.3 6.6
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Figure 1.  *Log transformed for statistical comparisons. Correlation between B12 and (A) BMI in cohort 1, 
(B) BMI in cohort 2, (C) Homocysteine in cohort 1, (D) Homocysteine in cohort 2, (E) MMA in cohort 1, (F) 
MMA in cohort 2, (G) SAM:SAH in cohort 1, (H) SAM:SAH in cohort 2. Cohort 1: n = 240; cohort 2: n = 60.
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In addition, in cohort 2 (Table 3), in the fully adjusted model, B12 showed independent, positive associa-
tions with HDL-C (β = 0.442, 95% CI (0.011, 0.873), p = 0.045). We also found that low maternal B12 during 
early pregnancy was associated with higher triglycerides in the unadjusted model, but after adjustment for all 
potential confounders, this association was not significant. However, we found that methionine (β = − 0.656, 95% 
CI − 0.900, − 0.412, p < 0.0001) and SAH (β = 0.371, 95% CI: 0.071, 0.672, p = 0.017) were associated significantly 
with higher triglycerides after adjusting for the confounders. This implies that higher triglycerides in B12 deficient 
women during early pregnancy could be mediated by these metabolites.
Figure 2.  *Log transformed for statistical comparisons. Correlation between B12 and (A) Triglycerides in 
cohort 2, (B) HDL-C in cohort 2. Cohort 2: n = 60.
Table 2.  Multiple regression analysis of B12 with BMI in early pregnancy. *Log transformed for statistical 
comparisons, β represents SDS change in the dependent variable per SDS change in the independent variable. 
SAM—S-adenosyl methionine, SAH—S-adenosyl homocysteine, MMA—Methyl malonic acid. Model 1: 
Unadjusted. Model 2: Model 1 + Adjusted for age, smoking, alcohol, parity, socio-economic status, B12, folate. 
Model 3: Model 2 + Adjusted for homocysteine, MMA, methionine, SAM and SAH.
BMI*
Cohort 1 Cohort 2
Β 95% CI p Β 95% CI p
Model 1
B12* − 0.237 (− 0.377, − 0.097) 0.001 − 0.564 (− 0.787, − 0.314)  < 0.0001
Model 2
Age 0.017 (− 0.011, 0.046) 0.229 − 0.033 (− 0.068, 0.001) 0.059
Smoking − 0.191 (− 0.542, 0.161) 0.287 0.003 (− 0.266, 0.273) 0.980
Alcohol 0.264 (− 0.047, 0.575) 0.096 − 0.002 (− 0.030, 0.025) 0.855
Parity 0.138 (− 0.167, 0.444) 0.372 0.196 (− 0.043, 0.436) 0.0106
Socio-economic status 0.045 (− 0.066, 0.155) 0.426 0.404 (0.293, 0.515)  < 0.0001
B12* − 0.187 (− 0.358, − 0.016) 0.032 − 0.185 (− 0.377, 0.007) 0.059
Folate* − 0.002 (− 0.162, 0.158) 0.982 0.142 (− 0.090, 0.374) 0.222
Model 3
Age 0.018 (− 0.010, 0.047) 0.205 − 0.020 (− 0.058, 0.018) 0.300
Smoking − 0.201 (− 0.559, 0.156) 0.268 0.016 (− 0.299, 0.331) 0.918
Alcohol 0.210 (− 0.107, 0.526) 0.193 − 0.006 (− 0.034, 0.022) 0.683
Parity 0.145 (− 0.160, 0.451) 0.350 0.208 (− 0.036, 0.452) 0.092
Socio-economic status 0.069 (− 0.046, 0.183) 0.239 0.372 (0.245, 0.499)  < 0.0001
B12* − 0.260 (− 0.440, − 0.079) 0.005 − 0.220 (− 0.424, − 0.016) 0.036
Folate* − 0.008 (− 0.175, 0.158) 0.923 0.102 (− 0.156, 0.360) 0.427
Homocysteine* − 0.054 (− 0.221, 0.112) 0.521 0.022 (− 0.223, 0.268) 0.853
MMA* − 0.177 (− 0.363, 0.010) 0.064 − 0.171 (− 0.359, 0.016) 0.072
Methionine* 0.123 (− 0.093, 0.339) 0.263 0.100 (− 0.098, 0.299) 0.312
SAM* 0.145 (− 0.012, 0.303) 0.070 0.056 (− 0.110, 0.222) 0.500
SAH* 0.015 (− 0.175, 0.205) 0.877 0.072 (− 0.114, 0.258) 0.436
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Discussion
Our study involving two cohorts with Caucasian women at early pregnancy from UK had three main findings. 
Firstly, vitamin B12 deficiency rates were 23% in cohort 1 and 18% in cohort 2. Secondly, low B12 level was 
associated with higher BMI and lower HDL-C. Thirdly, we found that lower levels of methionine and higher 
levels of SAH associated with higher triglycerides in these women at early pregnancy.
The prevalence of B12 deficiency in early pregnancy has been reported in very few studies. A recent sys-
tematic review showed that B12 deficiency were 21%, 19%, and 29% in the first, second and third trimesters, 
 respectively27. We found similar rates of deficiency of B12 (cohort 1–23% & cohort 2–18%) in our cohorts in early 
pregnancy. The regression analysis in cohort 1, after correcting for multiple confounders, we found that B12 is 
independently associated with BMI whereas in cohort 2, in addition to B12, social deprivation was also associated 
with BMI. The association between BMI and B12 has been shown in other studies in pregnant  women15,16,17 but 
also in  adolescents14 and in women of childbearing  age28. In addition, B12 deficiency may be causally related to 
 dysglycaemia9. It is therefore conceivable that if women with higher prevalence of B12 deficiency enter pregnancy, 
it may predispose them to greater risk of obesity, dyslipidemia and hyperglycaemia. However, longitudinal studies 
are required to investigate whether low B12 in early pregnancy increases the risk of incident GDM.
In a recent meta-analysis, we reported that maternal low HDL-C and high triglycerides at different trimesters 
of pregnancy are associated with higher birthweight, higher risk of large for gestational age and  macrosomia29. 
The present study showed that lower B12 was associated with lower HDL-C levels in early pregnancy. In our 
previous study of pregnant women at third trimester a similar association was  seen26. Consistent to this, Knight 
et al.6 showed this relationship in women at 28 weeks of gestation in the UK and Saraswathy et al.30 in a non-
pregnant adult population in India. In addition, our mechanistic studies in adipocytes indicate that in low B12 
status, hypomethylation of the lipid transcription factors (SREBF1 and LDLR)2 and alteration of  miRNAs3 could 
adversely regulate the adipogenic and lipogenic genes and promote dyslipidaemia.
We also observed that in addition to the effect of B12 deficiency on lipid regulation, metabolites such as 
lower methionine and higher SAH were associated with higher triglycerides. This was similar to our previous 
observation in a small study of 30 pregnant women in early pregnancy, where the tHcy and 1C metabolites (SAM, 
Table 3.  Multiple regression analysis of B12 with triglycerides and HDL-C at early pregnancy. *Log 
transformed for statistical comparisons, β represents SDS change in the dependent variable per SDS change in 
the independent variable. SAM – S-adenosyl methionine, SAH—S-adenosyl homocysteine, MMA—Methyl 
malonic acid; Model 1: Unadjusted. Model 2: Model 1 + Adjusted for age, smoking, alcohol, parity, socio-
economic status, BMI, B12, folate. Model 3: Model 2 + Adjusted for homocysteine, MMA, methionine, SAM 
and SAH.
Cohort 2
Triglycerides* HDL-C*
Β 95% CI p Β 95% CI p
Model 1
B12* − 0.378 (− 0.660, − 0.095) 0.010 0.506 (0.268, 0.744)  < 0.0001
Model 2
Age − 0.061 (− 0.137, 0.015) 0.111 0.059 (− 0.005, 0.124) 0.069
Smoking 0.354 (− 0.153, 0.860) 0.165 0.128 (− 0.334, 0.589) 0.577
Alcohol 0.040 (− 0.011, 0.091) 0.122 − 0.013 (− 0.060, 0.035) 0.587
Parity 0.262 (− 0.267, 0.790) 0.321 − 0.082 (− 0.526, 0.362) 0.708
Socio-economic status 0.116 (− 0.243, 0.475) 0.515 − 0.104 (− 0.428, 0.220) 0.520
BMI* − 0.058 (− 0.794, 0.678) 0.874 − 0.103 (− 0.668, 0.663) 0.970
B12* − 0.317 (− 0.703, 0.068) 0.103 0.515 (0.161, 0.869) 0.006
Folate* − 0.126 (− 0.591, 0.339) 0.584 − 0.210 (− 0.621, 0.200) 0.305
Model 3
Age − 0.056 (− 0.110, − 0.001) 0.046 0.065 (− 0.005, 0.135) 0.060
Smoking 0.520 (0.124, 0.917) 0.012 − 0.063 (− 0.614, 0.489) 0.817
Alcohol 0.034 (− 0.003, 0.070) 0.069 − 0.013 (− 0.064, 0.038) 0.599
Parity 0.162 (− 0.210, 0.534) 0.380 − 0.066 (− 0.534, 0.403) 0.776
Socio-economic status 0.033 (− 0.237, 0.303) 0.806 − 0.018 (− 0.379, 0.342) 0.917
BMI* − 0.045 (− 0.638, 0.549) 0.878 − 0.123 (− 0.945, 0.699) 0.762
B12* − 0.212 (− 0.529, 0.105) 0.182 0.442 (0.011, 0.873) 0.045
Folate* − 0.284 (− 0.650, 0.082) 0.123 − 0.220 (− 0.702, 0.261) 0.357
Homocysteine* 0.240 (− 0.081, 0.561) 0.136 − 0.244 (− 0.681, 0.192) 0.262
MMA* − 0.005 (− 0.267, 0.256) 0.966 − 0.085 (− 0.435, 0.264) 0.622
Methionine* − 0.656 (− 0.900, − 0.412) < 0.0001 0.113 (− 0.212, 0.437) 0.483
SAM* 0.252 (− 0.007, 0.511) 0.056 0.094 (− 0.262, 0.450) 0.592
SAH* 0.371 (0.071, 0.672) 0.017 0.043 (− 0.292, 0.378) 0.795
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SAM:SAH) were independently associated with  triglycerides20. A study in Netherlands in women of reproduc-
tive age, found that BMI was the strongest determinant of SAM and SAH  concentrations31. Lind et al. showed 
in people with the metabolic syndrome, the 1C metabolites were determinants of markers of adiposity such as 
BMI, body fat percentage and  IR22. Plasma SAH has been shown to be better indicator of cardiovascular disease 
than  tHcy32 and in vitro models have shown that elevated SAH adversely altered adipocyte function and altered 
 methylation33. In vascular disease, global DNA methylation was altered with a concomitant increase in plasma 
tHcy and  SAH34. Of further interest, a recent study by Knight et al. demonstrated that five out of thirteen 1C 
metabolites changed over pregnancy and these metabolites were associated with altered methylation levels of 
genes involved in neuronal and developmental process in both maternal and cord  blood23. These findings add to 
the evidence that alteration in the indices of 1C metabolism in B12 deficient status could change the methylation 
potential, mediate the epigenetic modifications and contribute to adverse lipid levels and metabolic outcomes. 
Thus, circulating levels of indices of 1C metabolism could be used as a surrogate for cellular level methylation 
capacity in early pregnancy. As the biomarkers of cellular methylation are related to health and disease and 
influenced by micronutrients, it would therefore be of interest to further study this hypothesis in human trials 
or animal studies to show whether B-vitamins supplementation in peri-conceptional period reduces metabolic 
risk of the offspring by altering these methylation biomarkers.
The strengths of this study are that we included two cohorts of pregnant women from UK at 16–18 weeks of 
gestation. Detailed information of lifestyle, socio-economic status and methylation biomarkers were available 
for both the cohorts, which allowed to control for multiple potential confounders. The rate of B12 deficiency 
and the factors associated with obesity in the two settings increases the generalizability of findings. However, 
we acknowledge the following limitations. This study is observational in a single time point, so causality can-
not be established. The lack of associations observed in other indices of 1C metabolism may well be due to our 
sample size and hence future investigations should include larger sample size. We did not have lipid levels or 
holo-transcobalamin levels in the first cohort. However, the independent associations seen with B12 and BMI 
in both the cohorts as well as the associations with B12/methionine/SAH and HDL-C/triglyceride levels despite 
the smaller size of cohort 2, warrants further investigation in larger studies. Finally, our study focussed only on 
some of the indices of the methionine cycle (and serum folate). Future studies measuring the entire 1C metabolite 
pathway (including the trans-sulphuration pathway) in early pregnancy, may provide more insights into cellular 
methylation potential and other epigenetic mechanisms.
In summary, our novel study highlighted that underlying nutritional (B12) status is an effective modifier of 
some of the 1C metabolites in early pregnancy. B12 deficiency in early pregnancy is adversely associated with 
altered level of 1C metabolites, maternal obesity and dyslipidaemia. These findings may have vital implications 
for pregnant women and their offspring, especially if they are overweight and obese. Out study suggests that 
assessment of B12 levels for women planning pregnancy may be worthwhile. Future investigations focusing on 
metabolites involved in 1C cycle associated with maternal and fetal outcomes is warranted for targeted interven-
tion and obesity prevention in both mother and offspring.
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